- Galectin Therapeutics (GALT -13.9%) is having a rough session.
- The shares rose 76% late last week, as investors clamored for liver disease plays in the wake of Intercept Pharmaceuticals' monumental rally.
- Today, the company announced the completion of patient enrollment "in the first cohort of a Phase 1 trial of GR-MD-02."
- The study will evaluate the "safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis." (PR)
at CNBC.com (Jul 23, 2012)